Literature DB >> 23504108

Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response.

Jessica Anna Cintolo1, Julia Tchou, Daniel A Pryma.   

Abstract

Positron emission tomography (PET) is an imaging modality that using radiotracers, permits real-time dynamic monitoring of biologic processes such as cell metabolic behavior and proliferation, and has proven useful as a research tool for understanding tumor biology. While it does not have a well-defined role in breast cancer for the purposes of screening, diagnosis, or prognosis, emerging PET technologies and uses could expand the applications of PET in breast cancer. Positron emission mammography may provide an alternative adjunct imaging modality for the screening and diagnosis of high-risk patients unable to tolerate MRI. The development of radiotracers with the ability to measure hormonal activity could provide a non-invasive way to assess hormone receptor status and functionality. Finally, the role of PET technologies in monitoring early treatment response may prove particularly useful to research involving new therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23504108     DOI: 10.1007/s10549-013-2451-z

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  4 in total

1.  Automated synthesis and dosimetry of 6-deoxy-6-[(18)F]fluoro-D-fructose (6-[(18)F]FDF): a radiotracer for imaging of GLUT5 in breast cancer.

Authors:  Vincent Bouvet; Hans S Jans; Melinda Wuest; Olivier-Mohamad Soueidan; John Mercer; Alexander Jb McEwan; Frederick G West; Chris I Cheeseman; Frank Wuest
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-04-25

2.  Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer.

Authors:  Kenjiro Aogi; Takayuki Kadoya; Yoshifumi Sugawara; Sachiko Kiyoto; Hideo Shigematsu; Norio Masumoto; Morihito Okada
Journal:  Breast Cancer Res Treat       Date:  2015-02-20       Impact factor: 4.872

3.  The Landscape of Clinical Trials Evaluating the Theranostic Role of PET Imaging in Oncology: Insights from an Analysis of ClinicalTrials.gov Database.

Authors:  Yu-Pei Chen; Jia-Wei Lv; Xu Liu; Yuan Zhang; Ying Guo; Ai-Hua Lin; Ying Sun; Yan-Ping Mao; Jun Ma
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

4.  Relation between primary tumor FDG avidity and site of first distant metastasis in patients with breast cancer.

Authors:  Chae Hong Lim; Seung Hwan Moon; Young Seok Cho; Young-Hyuck Im; Yearn Seong Choe; Byung-Tae Kim; Kyung-Han Lee
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.